Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
about
Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives.Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.Cytoreductive nephrectomy in the era of targeted therapies: a review.Renal cell carcinoma: new insights and challenges for a clinician scientist.Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapyRole of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis.Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis.[Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study.A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.Renal cell carcinoma: An update for the practicing urologist.
P2860
Q26783520-96E93D29-EB5D-4A3F-88D5-D5FB7D769718Q31109447-61DCD4E0-42D4-403F-A755-C5FE55F84431Q33665043-DAECA00F-87E6-41A8-9339-9CBA042432B2Q33740717-CA282907-17C3-427D-A166-36E026DBC634Q36261983-6C8270B9-B6D9-4E0A-8EC9-D76A885AA89BQ38202061-E04FBAD7-0A67-482D-82A7-5597C8F9BF80Q38543085-F5708FCD-06DB-431C-9207-F1E2EB9419DDQ38681585-FD3F3DE0-43C8-4190-87EB-6347457F423FQ38727698-BD9D5F53-BD9C-40DA-876E-F092B51D2C3DQ39216342-759401F4-0D11-4503-8E5B-DA3090D7AF36Q39222755-6D6EB07F-58DA-40A5-931C-BC2728876E30Q39505971-CFC5C55D-E34E-443E-8FA9-77A90152B753Q40604822-EA820CE9-DCDF-4A7F-AF77-39FA04E7BAA2Q40685017-4B475387-AD76-4E4B-BE8B-D9892584AD26Q41971524-55D0C942-256A-4A0C-BE4D-83AF8FA54C7EQ48246088-DD3C65EA-0AF6-4CC0-891A-DCDF07BF24E2Q50217752-FA5E11B8-6353-437C-9EF7-3B3085DE480AQ50791794-DE28F952-8EA4-438C-A1E9-74A66B2713BBQ51557110-D801B065-170B-46E4-A7A7-FC30708121B3Q51735339-26B5A31A-3D18-4B6B-9750-5AA1934D8512Q51737731-AA7086E0-B9E5-4040-90C7-37575AE69E12Q53649433-9AD3B665-7022-45C9-90F2-C6539357DE10
P2860
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Utilization of cytoreductive n ...... l in the targeted therapy era.
@en
Utilization of cytoreductive n ...... l in the targeted therapy era.
@nl
type
label
Utilization of cytoreductive n ...... l in the targeted therapy era.
@en
Utilization of cytoreductive n ...... l in the targeted therapy era.
@nl
prefLabel
Utilization of cytoreductive n ...... l in the targeted therapy era.
@en
Utilization of cytoreductive n ...... l in the targeted therapy era.
@nl
P2093
P2860
P356
P1476
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era
@en
P2093
Benjamin I Chung
Glenn M Chertow
I-Chun Thomas
James D Brooks
Judith C Hagedorn
Sandy Srinivas
Simon L Conti
Todd H Wagner
P2860
P304
P356
10.1002/IJC.28553
P577
2014-05-01T00:00:00Z